IVRS and the NIAC Consortium Receive a Prestigious Eurostars Grant for Drug Development on Renal Cell Carcinoma
Exciting news! IVRS AB is proud to be a key partner in the NIAC consortium, recently awarded a €1.36M Eurostars grant for groundbreaking renal cell carcinoma (RCC) research! We’ll be leveraging our cutting-edge in vivo RCC models and whole-body 3D imaging to evaluate a novel inhibitor developed by AtG Therapeutics. This promising therapeutic could offer new hope for […]
New segment model on human lung cancer
We are thrilled to launch our new model of Non-Small Cell Lung Cancer. We use patient-derived xenografts as well as mouse allografts to replicate clinical features of this devastating condition. Join us today on our quest for accelerating preclinical drug discovery and combating lung cancer. Explore this and other segment models here: https://ivrs.se/segment-models/ If you have […]
Fantastic news! IVRS AB has received a Nordiskt Tillväxtcertifikat
We continue growing!
IVRS launches a new segment model on Human Glioblastoma!
We are excited to launch our new orthotopic model of human glioblastoma. We use cutting-edge technology such as patient-derived xenografts (PDX) and in vivo bioluminescence imaging. Join us today on our quest for accelerating preclinical drug discovery and combating brain cancer. Explore this and other segment models here: https://ivrs.se/segment-models/ If you have any questions or would […]
New segment model on human breast cancer for preclinical drug validation!
We constantly work to develop clinically relevant models to provide reliable platforms for preclinical drug validation. Today, we are thrilled to announce the launch of our second segment model on human breast cancer, using orthotopic transplantation of patient-derived xenografts (PDX) and in vivo bioluminescence imaging. All of these essential components are conducted in-house, ensuring seamless […]
IVRS is launching a segment model on human pancreatic cancer!
Introducing our pancreatic cancer segment model. At IVRS AB we are constantly working on ways to expand our service array with robust and clinically relevant methods. We are thus proud to introduce a series of segment models, starting with our platform to validate drug candidates targeting pancreatic cancer. Our approach to a successful validatory study combines orthotopic […]
